Literature DB >> 8837978

Estimation of the time course of slow-wave sleep over the night in depressed patients: effects of clomipramine and clinical response.

C L Ehlers1, J W Havstad, D J Kupfer.   

Abstract

The distribution of slow-wave activity during sleep has been analyzed using a method related to the two-process model of sleep regulation. This method is applied to the analyses of data collected from 21 inpatients with unipolar depression who received the antidepressant clomipramine (CMI) in a pulse-loading protocol. CMI infusion was found to redistribute slow-wave activity, producing more concentration in the early part of the night, and also significantly reduced the fluctuation in slow-wave power as a function of time. These measures also distinguished clinical responders from the nonresponders. Drug responders had a significant redistribution of slow-wave activity to the earlier part of the night as compared to nonresponders. This suggests that measures of the distribution of slow-wave activity over the night may represent a good measure of clinical response to antidepressant therapy and have implications for the interpretation of the two-process model and sleep in depression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837978     DOI: 10.1016/0006-3223(95)00139-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

1.  Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder.

Authors:  Wallace C Duncan; Jessica Selter; Nancy Brutsche; Simone Sarasso; Carlos A Zarate
Journal:  J Affect Disord       Date:  2012-08-05       Impact factor: 4.839

Review 2.  Antidepressants and sleep: a qualitative review of the literature.

Authors:  Sue Wilson; Spilios Argyropoulos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants.

Authors:  Okko Alitalo; Roosa Saarreharju; Ioline D Henter; Carlos A Zarate; Samuel Kohtala; Tomi Rantamäki
Journal:  Prog Neurobiol       Date:  2021-08-14       Impact factor: 10.885

Review 4.  Human biomarkers of rapid antidepressant effects.

Authors:  Carlos A Zarate; Daniel C Mathews; Maura L Furey
Journal:  Biol Psychiatry       Date:  2013-01-29       Impact factor: 13.382

5.  Spectral EEG sleep profiles as a tool for prediction of clinical response to antidepressant treatment.

Authors:  Jean-Paul Macher; Rémy Luthringer; Luc Staner
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

6.  Manipulating the sleep-wake cycle and circadian rhythms to improve clinical management of major depression.

Authors:  Ian B Hickie; Sharon L Naismith; Rébecca Robillard; Elizabeth M Scott; Daniel F Hermens
Journal:  BMC Med       Date:  2013-03-22       Impact factor: 8.775

Review 7.  Neural Plasticity Is Involved in Physiological Sleep, Depressive Sleep Disturbances, and Antidepressant Treatments.

Authors:  Meng-Qi Zhang; Rui Li; Yi-Qun Wang; Zhi-Li Huang
Journal:  Neural Plast       Date:  2017-10-18       Impact factor: 3.599

8.  The Effect Of Fluvoxamine On Sleep Architecture Of Depressed Patients With Insomnia: An 8-Week, Open-Label, Baseline-Controlled Study.

Authors:  Yanli Hao; Yuanyuan Hu; Haili Wang; Dhirendra Paudel; Yan Xu; Bin Zhang
Journal:  Nat Sci Sleep       Date:  2019-11-04

Review 9.  Association of Sleep Architecture and Physiology with Depressive Disorder and Antidepressants Treatment.

Authors:  Peter Hutka; Michaela Krivosova; Zuzana Muchova; Ingrid Tonhajzerova; Andrea Hamrakova; Zuzana Mlyncekova; Juraj Mokry; Igor Ondrejka
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

Review 10.  Sleep Disturbances and Depression Are Co-morbid Conditions: Insights From Animal Models, Especially Non-human Primate Model.

Authors:  Meng Li; Jieqiong Cui; Bonan Xu; Yuanyuan Wei; Chenyang Fu; Xiaoman Lv; Lei Xiong; Dongdong Qin
Journal:  Front Psychiatry       Date:  2022-01-25       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.